Phase 2 N=107 Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Lung Cancer · Tobacco Use Disorder
Primary: Urinary Levels of Biomarkers of NNK Metabolism — 42.8; 0.36; 0.28; 49.7 pmol/mg creatinine
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=69 Essentiality of INH in TB Therapy
Tuberculosis
Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…
Phase 2 N=30 Tofacitnib for the Treatment of Alopecia Areata and Variants
Alopecia Areata (AA) · Alopecia Totalis (AT) · Alopecia Universalis (AU)
Primary: Mean Change in Severity of Alopecia Tool (SALT) Score — 22.8 percent change in SALT score
Phase 2 N=9 Oxytocin Treatment of Alcohol Dependence
Alcohol Withdrawal · Alcohol Dependence
Primary: Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score — -2.76; 1.01 units on a scale
Phase 2 N=69 PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…
Phase 2 N=33 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
Psoriasis
Primary: Change From Baseline in the Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) Score at the End of Treatment (EOT) (Week 24) or at the Last Assessment…
Phase 2 N=26 Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial
Central Neuropathic Pain · Allodynia · Spinal Cord Injury
Primary: Mean Pain Intensity (Percent Change From Baseline) — -0.006; -0.018; -0.073; -0.24 Percent change from baseline
Phase 2 N=39 Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I: Maximum Tolerated Dose of Plerixafor Plus G-CSF When Combined With MEC — 750 mcg/kg/day
Phase 2 N=31 Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Confirmed Response Rate (Partial or Complete Response for 2 Consecutive Evaluations at Least 4 Weeks Apart) as Measured by RECIST Criteria — 9; 13 percentage of patients…
Phase 2 N=36 Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Six-month Progression-free Survival (PFS) Rate at 6 Months — 39 percentage of patients
Phase 2 N=418 Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: 2-Year Progression Free Survival (PFS) Rate — 0.64; 0.71; 0.74 proportion of participants
Phase 2 N=289 Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
Breast Cancer · Cancer Survivor · Hot Flashes
Primary: The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. — 16.02; 15.35; 17.28; 14.28 units on a scale — p=0.13
Phase 2 N=94 Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Metastatic Renal Cell Carcinoma
Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants
Phase 2 N=150 Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Rash
Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769
Phase 2 N=78 Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
Cancer
Primary: 2-year Progression-free Survival (PFS) — 79; 75 percentage of participants